TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Trial of Zinc and Micronutrients in Tanzanian Children
Brief Summary: A randomized clinical trial of multiple micronutrients, zinc, zinc + micronutrients, or placebo among 2400 children born to HIV-negative Tanzanian mothers.


Options:
A: Arm Label: Multivitamins; Type: EXPERIMENTAL; Interventions: Drug: Multivitamins | Arm Label: Multivitamins + Zinc; Type: EXPERIMENTAL; Interventions: Drug: Zinc, Drug: Multivitamins | Arm Label: Zinc; Type: EXPERIMENTAL; Interventions: Drug: Zinc | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Zinc; Assigned to Arm(s): Multivitamins + Zinc, Zinc | Intervention Type: DRUG; Name: Multivitamins; Assigned to Arm(s): Multivitamins, Multivitamins + Zinc | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Other: Nutritional Counselling and Education | Arm Label: B; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Micronutrient Supplementation without Zinc | Arm Label: C; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Micronutrient Supplementation with Zinc | Intervention Type: DIETARY_SUPPLEMENT; Name: Micronutrient Supplementation without Zinc; Assigned to Arm(s): B | Intervention Type: DIETARY_SUPPLEMENT; Name: Micronutrient Supplementation with Zinc; Assigned to Arm(s): C | Intervention Type: OTHER; Name: Nutritional Counselling and Education; Assigned to Arm(s): A
C: Intervention Type: DRUG; Name: zinc sulphate dietary supplement; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: iron sulphate-folic acid dietary supplement; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Vitamin + Zinc + micronutrient mixture; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Vitamin A; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Vitamin A + Zinc; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: GlObal Secondary Prevention strategiEs to Limit Event Recurrence After Myocardial Infarction. GOSPEL Study
Brief Summary: Cardiac rehabilitation programmes are a proven treatment for individuals with recent myocardial infarction, resulting in reduced morbidity and mortality compared to usual care. Unfortunately, following completion of a cardiac rehabilitation programme, risk factors and lifestyle behaviours may deteriorate. The GOSPEL study investigates the benefits of a programme of continued educational and behavioural intervention to achieve optimal long-term secondary prevention goals.


Options:
A: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Exercise training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: exercise training | Arm Label: intensive exercise training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Intensive exercise training | Intervention Type: BEHAVIORAL; Name: exercise training; Assigned to Arm(s): Exercise training | Intervention Type: BEHAVIORAL; Name: Intensive exercise training; Assigned to Arm(s): intensive exercise training
B: Arm Label: Comprehensive phase one rehabilitation; Type: EXPERIMENTAL; Interventions: Other: Comprehensive phase one rehabilitation | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Comprehensive phase one rehabilitation; Assigned to Arm(s): Comprehensive phase one rehabilitation
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Rehabilitation in institution | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Rehabilitation at home, Behavioral: Out-patient rehabilitation at the hospital | Intervention Type: BEHAVIORAL; Name: Rehabilitation in institution; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Rehabilitation at home; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Out-patient rehabilitation at the hospital; Assigned to Arm(s): 2
D: Intervention Type: BEHAVIORAL; Name: multifactorial continued educational - behavioural programme; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: GlObal Secondary Prevention strategiEs to Limit Event Recurrence After Myocardial Infarction. GOSPEL Study
Brief Summary: Cardiac rehabilitation programmes are a proven treatment for individuals with recent myocardial infarction, resulting in reduced morbidity and mortality compared to usual care. Unfortunately, following completion of a cardiac rehabilitation programme, risk factors and lifestyle behaviours may deteriorate. The GOSPEL study investigates the benefits of a programme of continued educational and behavioural intervention to achieve optimal long-term secondary prevention goals.


Options:
A: Arm Label: Collaborative care; Type: EXPERIMENTAL; Interventions: Other: Collaborative care | Arm Label: Usual care; Type: PLACEBO_COMPARATOR; Interventions: Other: Usual care | Intervention Type: OTHER; Name: Collaborative care; Assigned to Arm(s): Collaborative care | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Usual care
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Psychotherapy, Other: Usual cardiological care | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Information session, Other: Usual cardiological care | Intervention Type: BEHAVIORAL; Name: Psychotherapy; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Information session; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Usual cardiological care; Assigned to Arm(s): 1, 2
C: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Psycho edcuactional support; Type: EXPERIMENTAL; Interventions: Behavioral: Psychoeducational support | Intervention Type: BEHAVIORAL; Name: Psychoeducational support; Assigned to Arm(s): Psycho edcuactional support
D: Intervention Type: BEHAVIORAL; Name: multifactorial continued educational - behavioural programme; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: GlObal Secondary Prevention strategiEs to Limit Event Recurrence After Myocardial Infarction. GOSPEL Study
Brief Summary: Cardiac rehabilitation programmes are a proven treatment for individuals with recent myocardial infarction, resulting in reduced morbidity and mortality compared to usual care. Unfortunately, following completion of a cardiac rehabilitation programme, risk factors and lifestyle behaviours may deteriorate. The GOSPEL study investigates the benefits of a programme of continued educational and behavioural intervention to achieve optimal long-term secondary prevention goals.


Options:
A: Arm Label: Enhanced Internet-based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Tailored content, Behavioral: Generic Internet-based information, Behavioral: Discussion forum, Behavioral: Behavioral monitoring | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Generic Internet-based information, Behavioral: Discussion forum | Intervention Type: BEHAVIORAL; Name: Tailored content; Assigned to Arm(s): Enhanced Internet-based intervention | Intervention Type: BEHAVIORAL; Name: Generic Internet-based information; Assigned to Arm(s): Control, Enhanced Internet-based intervention | Intervention Type: BEHAVIORAL; Name: Discussion forum; Assigned to Arm(s): Control, Enhanced Internet-based intervention | Intervention Type: BEHAVIORAL; Name: Behavioral monitoring; Assigned to Arm(s): Enhanced Internet-based intervention
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: ALIVE | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: ALIVE; Assigned to Arm(s): Intervention
C: Intervention Type: BEHAVIORAL; Name: multifactorial continued educational - behavioural programme; Assigned to Arm(s): N/A
D: Arm Label: Quality improvement program; Type: OTHER; Interventions: Other: multifaceted strategy | Arm Label: Hospital standard treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: multifaceted strategy; Assigned to Arm(s): Quality improvement program

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: GlObal Secondary Prevention strategiEs to Limit Event Recurrence After Myocardial Infarction. GOSPEL Study
Brief Summary: Cardiac rehabilitation programmes are a proven treatment for individuals with recent myocardial infarction, resulting in reduced morbidity and mortality compared to usual care. Unfortunately, following completion of a cardiac rehabilitation programme, risk factors and lifestyle behaviours may deteriorate. The GOSPEL study investigates the benefits of a programme of continued educational and behavioural intervention to achieve optimal long-term secondary prevention goals.


Options:
A: Arm Label: Cardio fit; Type: EXPERIMENTAL; Interventions: Behavioral: CardioFit | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: CardioFit; Assigned to Arm(s): Cardio fit
B: Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Prehab Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Prehab Intervention | Intervention Type: BEHAVIORAL; Name: Prehab Intervention; Assigned to Arm(s): Prehab Intervention
C: Intervention Type: BEHAVIORAL; Name: multifactorial continued educational - behavioural programme; Assigned to Arm(s): N/A
D: Arm Label: Weight Loss; Type: EXPERIMENTAL; Interventions: Other: Weight Loss | Arm Label: Interval Training; Type: EXPERIMENTAL; Interventions: Other: Interval Training | Intervention Type: OTHER; Name: Interval Training; Assigned to Arm(s): Interval Training | Intervention Type: OTHER; Name: Weight Loss; Assigned to Arm(s): Weight Loss

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Double-Blind, Placebo- and Active-Control, Parallel-arm, Phase III Trial With Controlled Adjustment of Dose to Evaluate the Efficacy and Safety of CG5503 Extended-Release (ER) in Patients With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee
Brief Summary: The purpose of this trial is to evaluate the effectiveness (level of pain control) and safety of orally administered tapentadol (CG5503) Extended Release (ER) (base) at doses of 100-250 mg twice daily in patients with moderate to severe chronic pain due to osteoarthritis of the knee, in comparison with placebo and Oxycodone Controlled Release (CR).


Options:
A: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: tapentadol (CG5503) | Arm Label: 002; Type: ACTIVE_COMPARATOR; Interventions: Drug: oxycodone | Arm Label: 003; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: oxycodone; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: tapentadol (CG5503); Assigned to Arm(s): 001
B: Arm Label: Tapentadol Prolonged Release; Type: EXPERIMENTAL; Interventions: Drug: Tapentadol Prolonged Release | Intervention Type: DRUG; Name: Tapentadol Prolonged Release; Assigned to Arm(s): Tapentadol Prolonged Release
C: Arm Label: Tapentadol (CG5503); Type: EXPERIMENTAL; Interventions: Drug: Tapentadol (CG5503) ER | Arm Label: Oxycodone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxycodone CR | Intervention Type: DRUG; Name: Oxycodone CR; Assigned to Arm(s): Oxycodone | Intervention Type: DRUG; Name: Tapentadol (CG5503) ER; Assigned to Arm(s): Tapentadol (CG5503)
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: CG5503; Type: EXPERIMENTAL; Interventions: Drug: CG5503 | Intervention Type: DRUG; Name: CG5503; Assigned to Arm(s): CG5503 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label, Multicentre, Long-Term Extension Study of Etanercept in Ankylosing Spondylitis
Brief Summary: The primary objective of this study was to determine the long-term safety of etanercept in adults with AS who had completed study 0881A3-311-EU.


Options:
A: Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: infliximab+azathioprine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: methylprednisolone or budesonide | Intervention Type: DRUG; Name: infliximab+azathioprine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: methylprednisolone or budesonide; Assigned to Arm(s): 2
D: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo (control procedure) | Arm Label: Epidural injection of etanercept; Type: EXPERIMENTAL; Interventions: Drug: epidural injection of etanercept | Intervention Type: DRUG; Name: epidural injection of etanercept; Assigned to Arm(s): Epidural injection of etanercept | Intervention Type: DRUG; Name: placebo (control procedure); Assigned to Arm(s): 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes: A 20-week Randomised, Double-blind, Placebo-controlled, Six Armed Parallel Group, Multi-centre, Multinational Trial With an Open Label Orlistat Comparator Arm and With an 84-week Extension Period
Brief Summary: This trial is conducted in Europe. The purpose of the 20-week trial is to investigate the efficacy of liraglutide to induce body weight loss and the purpose of the extension is to evaluate the long term safety and tolerability of liraglutide.

Trial has the following trial periods: A 20-week randomised, double-blind, placebo-controlled, six-armed parallel-group, multi-centre, multinational trial with an open label orlistat comparator arm followed by an 84 week extension period.


Options:
A: Arm Label: Liraglutide 3.0 mg; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide 3.0 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: liraglutide; Type: ACTIVE_COMPARATOR; Interventions: Drug: liraglutide | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): liraglutide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
C: Arm Label: Lira placebo/Lira 2.4 mg/Lira 3.0 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Lira 1.2 mg/Lira 3.0 mg; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Lira 1.8 mg/Lira 3.0 mg; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Lira 2.4 mg/Lira 3.0 mg; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Liraglutide 3.0 mg; Type: EXPERIMENTAL; Interventions: Drug: liraglutide, Drug: placebo | Arm Label: Orlistat; Type: ACTIVE_COMPARATOR; Interventions: Drug: orlistat | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Lira 1.2 mg/Lira 3.0 mg, Lira 1.8 mg/Lira 3.0 mg, Lira 2.4 mg/Lira 3.0 mg, Liraglutide 3.0 mg | Intervention Type: DRUG; Name: orlistat; Assigned to Arm(s): Orlistat | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Lira placebo/Lira 2.4 mg/Lira 3.0 mg, Liraglutide 3.0 mg
D: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Drug: exenatide | Arm Label: Group B; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: exenatide; Assigned to Arm(s): Group A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Group B

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Comparative (Double-blind, Double-dummy) Randomised, Multi-centre Study to Assess the Efficacy of Pyronaridine Artesunate (180:60mg) Versus Coartem® (Artemether Lumefantrine) in Children & Adult Patients With Falciparum Malaria
Brief Summary: The primary objective of this phase III study is to compare the efficacy and safety of the fixed combination of pyronaridine artesunate (Pyramax®, PA) with that of Coartem® (artemether lumefantrine, AL) in children and adults with uncomplicated P falciparum malaria in Africa and South East Asia.


Options:
A: Arm Label: Pyronaridine-artesunate; Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine-artesunate | Arm Label: Artemether-lumefantrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Artemether-lumefantrine combination | Intervention Type: DRUG; Name: Pyronaridine-artesunate; Assigned to Arm(s): Pyronaridine-artesunate | Intervention Type: DRUG; Name: Artemether-lumefantrine combination; Assigned to Arm(s): Artemether-lumefantrine
B: Arm Label: PA group; Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine artesunate | Arm Label: AL group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Coartem® (artemether lumefantrine) | Intervention Type: DRUG; Name: Pyronaridine artesunate; Assigned to Arm(s): PA group | Intervention Type: DRUG; Name: Coartem® (artemether lumefantrine); Assigned to Arm(s): AL group
C: Arm Label: pyronaridine artesunate; Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine artesunate | Arm Label: chloroquine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chloroquine | Intervention Type: DRUG; Name: Pyronaridine artesunate; Assigned to Arm(s): pyronaridine artesunate | Intervention Type: DRUG; Name: Chloroquine; Assigned to Arm(s): chloroquine
D: Arm Label: PA group; Type: EXPERIMENTAL; Interventions: Drug: pyronaridine artesunate | Arm Label: AL group; Type: ACTIVE_COMPARATOR; Interventions: Drug: arthemeter lumefantrine | Intervention Type: DRUG; Name: pyronaridine artesunate; Assigned to Arm(s): PA group | Intervention Type: DRUG; Name: arthemeter lumefantrine; Assigned to Arm(s): AL group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Comparative (Double-blind, Double-dummy) Randomised, Multi-centre Study to Assess the Efficacy of Pyronaridine Artesunate (180:60mg) Versus Coartem® (Artemether Lumefantrine) in Children & Adult Patients With Falciparum Malaria
Brief Summary: The primary objective of this phase III study is to compare the efficacy and safety of the fixed combination of pyronaridine artesunate (Pyramax®, PA) with that of Coartem® (artemether lumefantrine, AL) in children and adults with uncomplicated P falciparum malaria in Africa and South East Asia.


Options:
A: Arm Label: PA group; Type: EXPERIMENTAL; Interventions: Drug: pyronaridine artesunate | Arm Label: AL group; Type: ACTIVE_COMPARATOR; Interventions: Drug: arthemeter lumefantrine | Intervention Type: DRUG; Name: pyronaridine artesunate; Assigned to Arm(s): PA group | Intervention Type: DRUG; Name: arthemeter lumefantrine; Assigned to Arm(s): AL group
B: Arm Label: PA group; Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine artesunate | Arm Label: AL group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Coartem® (artemether lumefantrine) | Intervention Type: DRUG; Name: Pyronaridine artesunate; Assigned to Arm(s): PA group | Intervention Type: DRUG; Name: Coartem® (artemether lumefantrine); Assigned to Arm(s): AL group
C: Arm Label: arm 1; Type: EXPERIMENTAL; Interventions: Drug: Artesunate | Arm Label: arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Artesunate + Mefloquine | Intervention Type: DRUG; Name: Artesunate; Assigned to Arm(s): arm 1 | Intervention Type: DRUG; Name: Artesunate + Mefloquine; Assigned to Arm(s): arm 2
D: Arm Label: Pyronaridine - artesunate; Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine - artesunate | Arm Label: Mefloquine plus artesunate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mefloquine plus artesunate | Intervention Type: DRUG; Name: Pyronaridine - artesunate; Assigned to Arm(s): Pyronaridine - artesunate | Intervention Type: DRUG; Name: Mefloquine plus artesunate; Assigned to Arm(s): Mefloquine plus artesunate

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Comparative (Double-blind, Double-dummy) Randomised, Multi-centre Study to Assess the Efficacy of Pyronaridine Artesunate (180:60mg) Versus Coartem® (Artemether Lumefantrine) in Children & Adult Patients With Falciparum Malaria
Brief Summary: The primary objective of this phase III study is to compare the efficacy and safety of the fixed combination of pyronaridine artesunate (Pyramax®, PA) with that of Coartem® (artemether lumefantrine, AL) in children and adults with uncomplicated P falciparum malaria in Africa and South East Asia.


Options:
A: Arm Label: pyronaridine/artesunate (6:2 mg/kg); Type: EXPERIMENTAL; Interventions: Drug: pyronaridine/artesunate | Arm Label: pyronaridine/artesunate (9:3 mg/kg); Type: EXPERIMENTAL; Interventions: Drug: pyronaridine/artesunate | Arm Label: pyronaridine/artesunate (12:4 mg/kg); Type: EXPERIMENTAL; Interventions: Drug: pyronaridine/artesunate | Intervention Type: DRUG; Name: pyronaridine/artesunate; Assigned to Arm(s): pyronaridine/artesunate (12:4 mg/kg), pyronaridine/artesunate (6:2 mg/kg), pyronaridine/artesunate (9:3 mg/kg)
B: Arm Label: PA group; Type: EXPERIMENTAL; Interventions: Drug: pyronaridine artesunate | Arm Label: AL group; Type: ACTIVE_COMPARATOR; Interventions: Drug: arthemeter lumefantrine | Intervention Type: DRUG; Name: pyronaridine artesunate; Assigned to Arm(s): PA group | Intervention Type: DRUG; Name: arthemeter lumefantrine; Assigned to Arm(s): AL group
C: Arm Label: Pyronaridine - artesunate; Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine - artesunate | Arm Label: Mefloquine plus artesunate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mefloquine plus artesunate | Intervention Type: DRUG; Name: Pyronaridine - artesunate; Assigned to Arm(s): Pyronaridine - artesunate | Intervention Type: DRUG; Name: Mefloquine plus artesunate; Assigned to Arm(s): Mefloquine plus artesunate
D: Arm Label: PA group; Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine artesunate | Arm Label: AL group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Coartem® (artemether lumefantrine) | Intervention Type: DRUG; Name: Pyronaridine artesunate; Assigned to Arm(s): PA group | Intervention Type: DRUG; Name: Coartem® (artemether lumefantrine); Assigned to Arm(s): AL group

Answer: D